Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has provided an update.
Simcere Pharmaceutical Group Limited announced that its new drug application for Deunoxavir Marboxil Granules, an anti-influenza drug for pediatric patients, has been accepted by the National Medical Products Administration. This marks a significant milestone as it is China’s first pediatric anti-influenza virus innovative drug to complete phase III clinical trials and receive regulatory approval, potentially enhancing the company’s market position in the pharmaceutical industry.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation and R&D-driven pharmaceutical company based in Hong Kong, focusing on therapeutic areas such as neuroscience, anti-oncology, autoimmune, and anti-infection. The company is committed to addressing significant clinical needs through its in-house R&D efforts and strategic partnerships with innovative companies and research institutes.
Average Trading Volume: 24,456,184
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.84B
For detailed information about 2096 stock, go to TipRanks’ Stock Analysis page.